Brief: Bergenbio Announces Stopped Recruitment To The Bemcentinib Arm In UK Accord Covid Platform Trial

Oncoinvent ASA

30/03/2021 21:09

March 30 (Reuters) - Bergenbio ASA  BGBIO.OL :
    * BERGENBIO ANNOUNCES STOPPED RECRUITMENT TO THE BEMCENTINIB
ARM
IN UK ACCORD COVID PLATFORM TRIAL
    * NO SAFETY CONCERNS HAVE BEEN IDENTIFIED.
    * DECISION HAS BEEN MADE TO HALT UK RECRUITMENT AT 30
PATIENTS,
SIMILAR NUMBER OF MATCHED CONTROLS, ENABLING A PROMPT ANALYSIS
OF RESULTS
    * DATA FROM ACCORD STUDY AND BERGENBIO'S PHASE II COVID-19
TRIAL
STUDY WILL BE ANALYSED SEPARATELY
    * BERGENBIO ASA - DATA FROM ACCORD STUDY AND BERGENBIO'S
PHASE II
COVID-19 TRIAL STUDY WILL BE ANALYSED IN COMBINATION IN A
META-ANALYSIS
    * BERGENBIO- PHASE II TRIAL OF BEMCENTINIB FOR TREATMENT OF
COVID-19 IN HOSPITALISED PATIENTS IN SOUTH AFRICA AND INDIA
COMPLETED RECRUITMENT

Source text for Eikon:  ID:nWkrbkB5nj 
Further company coverage:  BGBIO.OL 

 ((Reuters.Briefs@thomsonreuters.com;))